Stocks Health care IOVA
NASDAQ · Health careIovance Biotherapeutics, Inc. (IOVA)
Iovance Biotherapeutics, Inc. brought in $379M of revenue over the twelve months to September 30, 2026, up 51.3% from a year earlier. It posted a net loss of $220.5M. In fiscal 2025 capital spending exceeded operating cash flow by $336.2M. At September 30, 2026 it held $57.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Iovance Biotherapeutics, Inc.
- Net worth
- Iovance Biotherapeutics, Inc. has a market value (market cap) of $3.7B at the latest share price, and shareholders' equity of $812.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $263.5M (+60.6% year on year), with a net loss of $391M. Over the 12 months to September 30, 2026: revenue $379M, net loss $220.5M.
- Cash flow
- In fiscal 2025 operations used $302.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Iovance Biotherapeutics, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Iovance Biotherapeutics, Inc. does
Iovance Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IOVA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $263.5M | -$391M | -$1.09 | -$336.2M |
| 2024 | $164.1M | -$372.2M | -$1.28 | -$364M |
| 2023 | $1.2M | -$444M | -$1.89 | -$384.1M |
| 2022 | n/a | -$395.9M | -$2.49 | -$313.2M |
| 2021 | n/a | -$342.3M | -$2.23 | -$265.5M |
| 2020 | n/a | -$259.6M | -$1.88 | -$251.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IOVA ranks in Health care
Latest SEC filings
What Iovance Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Other event 8-K
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 80% to $121.5M versus the same quarter last year; diluted EPS -$0.05 versus -$0.25.
- November 5, 2026
- October 29, 2026Other event 8-K
- October 5, 2026Other event 8-K
- September 29, 2026Other event 8-K
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Other event 8-K
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 66% to $99.3M versus the same quarter last year; diluted EPS -$0.11 versus -$0.33.
- August 6, 2026
Insider trades
What the people running Iovance Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 12 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 8, 2026 | Puri Raj K.Chief Regulatory Officer | Exercised options | 9,766 | - |
| September 8, 2026 | Puri Raj K.Chief Regulatory Officer | Shares withheld for tax | 4,478 | $39K |
| September 8, 2026 | Bilinsky IgorChief Operating Officer | Exercised options | 7,813 | - |
| September 8, 2026 | Bilinsky IgorChief Operating Officer | Shares withheld for tax | 3,976 | $34.6K |
| September 8, 2026 | Vogt Frederick GInterim CEO & General Counsel, Director | Exercised options | 15,626 | - |
| September 8, 2026 | Vogt Frederick GInterim CEO & General Counsel, Director | Shares withheld for tax | 6,638 | $57.8K |
| September 1, 2026 | Bilinsky IgorChief Operating Officer | Exercised options | 8,789 | - |
| September 1, 2026 | Bilinsky IgorChief Operating Officer | Shares withheld for tax | 4,472 | $37K |
Who owns IOVA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Quogue Capital LLC13D, may seek influence with 1 related filers | 11.6% | March 19, 2024 |
Largest institutional holders
Insiders
6 insiders reported holding 1,317,264 shares in total, about $10.6M at the last price.
| Holder | Shares |
|---|---|
| Vogt Frederick GInterim CEO & General Counsel, Director | 595,447 |
| Puri Raj K.Chief Regulatory Officer | 256,364 |
| Kirby Daniel GordonChief Commercial Officer | 154,511 |
| Bilinsky IgorChief Operating Officer | 142,074 |
| Graf Finckenstein FriedrichChief Medical Officer | 140,111 |
| Roche Corleen M.Chief Financial Officer | 28,757 |
Questions about IOVA
What does Iovance Biotherapeutics, Inc. do?
Iovance Biotherapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as IOVA. Its shares trade on NASDAQ under the ticker IOVA.
What is Iovance Biotherapeutics, Inc.'s net worth?
Iovance Biotherapeutics, Inc. has a market value (market cap) of $3.7B at the latest share price, and shareholders' equity of $812.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Iovance Biotherapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $220.5M on revenue of $379M.
How much revenue does Iovance Biotherapeutics, Inc. make?
Over the twelve months to September 30, 2026 Iovance Biotherapeutics, Inc. reported revenue of $379M. That is 51.3% more than a year earlier.
When did Iovance Biotherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Iovance Biotherapeutics, Inc.'s next earnings report?
Iovance Biotherapeutics, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IOVA with
Follow IOVA
Get an email when Iovance Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Iovance Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.